tetano
Editor, Senior Moderator
BMC Infect Dis
. 2021 Feb 8;21(1):156.
doi: 10.1186/s12879-021-05847-9.
Differences of blood cells, lymphocyte subsets and cytokines in COVID-19 patients with different clinical stages: a network meta-analysis
Wu Yan[SUP] #[/SUP][SUP] 1 2 [/SUP], Danrong Chen[SUP] #[/SUP][SUP] 1 2 [/SUP], Francis Manyori Bigambo[SUP] #[/SUP][SUP] 1 2 [/SUP], Hongcheng Wei[SUP] 1 2 [/SUP], Xu Wang[SUP] 3 [/SUP], Yankai Xia[SUP] 4 5 [/SUP]
Affiliations
Abstract
Background: Due to the rapid spread of coronavirus disease 2019 (COVID-19) worldwide, it is necessary to ascertain essential immune inflammatory parameters that describe the severity of the disease and provide guidance for treatment. We performed network meta-analyses to determine differences in blood cells, lymphocyte subsets, and cytokines in COVID-19 patients with different clinical stages.
Methods: Databases were systematically searched to May 2, 2020, and updated on June 1, 2020. Network meta-analyses were conducted via Stata 15.0, and the mean difference (MD) and its 95% CI were used as the effect values of the pooled analysis.
Results: Seventy-one studies were included involving 8647 COVID-19 patients, White blood cell (WBC), neutrophil (NEUT), IL-6, and IL-10 counts increased significantly with worsening of the COVID-19, while lymphocyte (LYM) counts decreased. The levels of platelet (PLT), CD3[SUP]+[/SUP], CD4[SUP]+[/SUP], CD8[SUP]+[/SUP], and CD19[SUP]+[/SUP] cells in severe and critical patients were significantly lower than those in mild patients. IL-1β count was significantly elevated in critical patients.
Conclusions: Immune suppression and inflammatory injury play crucial roles in the progression of COVID-19, and the identification of susceptible cells and cytokines provide guidance for the early and accurate treatment of COVID-19 patients.
Keywords: Blood cells; COVID-19; Clinical stages; Cytokines; Lymphocyte subsets; Network meta-analysis.
. 2021 Feb 8;21(1):156.
doi: 10.1186/s12879-021-05847-9.
Differences of blood cells, lymphocyte subsets and cytokines in COVID-19 patients with different clinical stages: a network meta-analysis
Wu Yan[SUP] #[/SUP][SUP] 1 2 [/SUP], Danrong Chen[SUP] #[/SUP][SUP] 1 2 [/SUP], Francis Manyori Bigambo[SUP] #[/SUP][SUP] 1 2 [/SUP], Hongcheng Wei[SUP] 1 2 [/SUP], Xu Wang[SUP] 3 [/SUP], Yankai Xia[SUP] 4 5 [/SUP]
Affiliations
- PMID: 33557779
- DOI: 10.1186/s12879-021-05847-9
Abstract
Background: Due to the rapid spread of coronavirus disease 2019 (COVID-19) worldwide, it is necessary to ascertain essential immune inflammatory parameters that describe the severity of the disease and provide guidance for treatment. We performed network meta-analyses to determine differences in blood cells, lymphocyte subsets, and cytokines in COVID-19 patients with different clinical stages.
Methods: Databases were systematically searched to May 2, 2020, and updated on June 1, 2020. Network meta-analyses were conducted via Stata 15.0, and the mean difference (MD) and its 95% CI were used as the effect values of the pooled analysis.
Results: Seventy-one studies were included involving 8647 COVID-19 patients, White blood cell (WBC), neutrophil (NEUT), IL-6, and IL-10 counts increased significantly with worsening of the COVID-19, while lymphocyte (LYM) counts decreased. The levels of platelet (PLT), CD3[SUP]+[/SUP], CD4[SUP]+[/SUP], CD8[SUP]+[/SUP], and CD19[SUP]+[/SUP] cells in severe and critical patients were significantly lower than those in mild patients. IL-1β count was significantly elevated in critical patients.
Conclusions: Immune suppression and inflammatory injury play crucial roles in the progression of COVID-19, and the identification of susceptible cells and cytokines provide guidance for the early and accurate treatment of COVID-19 patients.
Keywords: Blood cells; COVID-19; Clinical stages; Cytokines; Lymphocyte subsets; Network meta-analysis.